Treatment Experienced

Simeprevir versus Telaprevir with PR in GT1
ATTAIN Trial

Reddy KR, et al. Lancet Infect Dis. 2015;15:27-35.

Simeprevir vs Telaprevir with Peginterferon + Ribavirin in GT1 ATTAIN: Study Features

ATTAIN Trial: Features

- **Design**: Randomized, double-blind, phase 3, study evaluating simeprevir versus telaprevir with peginterferon alfa-2a plus ribavirin for treatment-experienced patients with genotype 1 chronic HCV
- **Setting**: International at 169 sites in 24 countries
- **Entry Criteria**
  - Chronic HCV genotype 1
  - HCV RNA > 10,000 IU/mL
  - Adults ≥ 18
  - Prior null or partial responder with prior peginterferon + ribavirin
  - Compensated liver disease
- **Exclusion Criteria**
  - Non-HCV-related liver disease, including hepatocellular carcinoma
  - Prior HCV treatment with medication other than peginterferon + ribavirin
  - Coinfection with HAV, HBV, HIV, or non-genotype 1 HCV
- **Primary End-Points**: Efficacy (SVR12)

Source: Reddy KR, et al. Lancet Infect Dis. 2015;15:27-35.

Simeprevir vs Telaprevir with Peginterferon + Ribavirin in GT1 ATTAIN: Study Design



Drug Dosing

Simeprevir: 150 mg once daily

Telaprevir: 750 mg three times daily

Peginterferon alfa-2a (PEG): 180 mcg/week

Ribavirin (RBV) weight-based (in 2 divided doses): 1000 mg if < 75kg or 1200 mg/day if ≥ 75kg

Source: Reddy KR, et al. Lancet Infect Dis. 2015;15:27-35.

Simeprevir vs Telaprevir with Peginterferon + Ribavirin in GT1 ATTAIN: Results

ATTAIN: SVR12 by Prior Treatment Response



PR = peginterferon plus ribavirin

Source: Reddy KR, et al. Lancet Infect Dis. 2015;15:27-35.

Simeprevir vs Telaprevir with Peginterferon + Ribavirin in GT1 ATTAIN: Conclusions

Interpretation: “Simeprevir once a day with peginterferon alfa-2a and ribavirin was well tolerated in HCV genotype 1-infected previous non-responders and was non-inferior to telaprevir, thus providing an alternative treatment in areas of the world where all-oral HCV regimens are not available or accessible.”

Source: Reddy KR, et al. Lancet Infect Dis. 2015;15:27-35.

This slide deck is from the University of Washington's *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online

www.hepatitisc.uw.edu

Hepatitis Web Study

http://depts.washington.edu/hepstudy/

Funded by a grant from the Centers for Disease Control and Prevention.

Hepatitis web study